Reverse DCF

Patanjali Foods: what the price is assuming

A normal DCF asks you to guess growth. Run backwards, it takes today's price and solves for the growth the market has already priced in — then you can judge whether this company can deliver it.

What the price assumes

Attractive

To justify its price of ₹341, this stock must grow earnings at 10% every year for 6 years. Our analysis caps realistic growth at ~14%. At that growth it is worth ₹425 — upside of 25%.

Growth the price implies
9.9% a year
for 6 years, fading to 3%
It has actually compounded at
37.8% a year
net profit, FY23–FY26 · EPS 37.8%
The gap
-0.0 pp
25% downside if it only repeats history
Price today ₹341 Value at the reference growth ₹424.77
Why this baseline, and what it is built on

PATANJALI has demonstrated a significant turnaround, moving from negative net profits in 2018-2019 to consistent and growing profitability since 2022, with recent annualized net profit growth exceeding 29% and sales growth around 14-15%. Operating profit margins have also shown improvement, from 2-3% to 4-6%, with management targeting 8-10% for the food business, indicating further room for profit expansion. Management's guidance for key segments, such as HPC exceeding 15% and Food growing 8-10%, combined with a decent promise track record (75% achieved/on-track), supports a defensible stage-1 growth rate of 14%. A 6-year stage-1 period is appropriate given the ongoing strategic initiatives, including oil palm plantation expansion targeted for FY27, allowing for sustained above-average growth before fading over 3 years to a conservative terminal growth of 3%. The suggested discount rate of 11% reflects the company's healthy leverage and improving financial stability, balanced against its past volatility.

  • — our target clearly is that we want to exceed 15% is what we have set on the overall basis as a growth objective for HPC and on a fully annualized basis.
  • — in the food space, we will grow between 8% to 10% will be our growth rate.
  • — Our margin construct in the food business will be between 8% and 10% as well. That EBITDA margin, that's what we are targeting.
  • — veg oil business, anywhere between 3% and 4% growth is what we target.
  • — The orientation in terms of the planning that is entirely done by the company is on the volume growth of between 3% and 4%.
  • — This year, our target is that we should do close to 40,000 additional hectares, which is a mix of 20,000 in the northeastern part of the country and 20,000 in the South India. And for that we need to prepare well in advance on getting our sprouts and nurseries and others. And we are very much on course for that. What I am saying this year is '26-27. I am talking now.

Through 2025-12-31

Your assumptions

Change any of these and the value moves. A valuation that flips on a one-point change in the required return is telling you something.

Value on these assumptions

₹425.65

Against today's price

+25%

9 projected years, then a terminal value at 3.0%.

Normalized net profit is discounted as a proxy for owner earnings, not full free cash flow. An analytical tool, not investment advice.

How to read this valuation

  1. Start from the price, not the forecast. A normal DCF asks you to guess growth and hands back a fair value. Run backwards, it takes today's price and solves for the earnings growth the market is already assuming.
  2. Compare that with what the company has done. The historical profit and EPS CAGR sit beside the implied number. A price that needs 25% a year from a business that has compounded at 10% is asking a lot, and the gap is the risk you are taking on.
  3. Then apply your own view. Change the growth rate, how long it lasts, how it fades and the return you require. A valuation that flips on a one-point change in the discount rate is telling you something about itself.
  4. Mind the caveats. Normalized net profit stands in for owner earnings, not full free cash flow; terminal growth is capped at 6%, roughly nominal GDP; cyclicals are flagged because a peak-earnings base overstates value. This is an analytical tool, not investment advice.